Xencor (XNCR) AI Stock Analysis

• Market Cap: $995.67M
• Dividend Yield: N/A
• Average Volume (3M): 1.12M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: -2.07%
• EPS Growth: 22.52%
• Country: US
• Employees: 250
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.41
• Shares Outstanding: 71,323,044
• 10 Day Avg. Volume: 981,594
• 30 Day Avg. Volume: 1,124,982
• PEG Ratio: -0.09
• Price to Book (P/B): 2.21
• Price to Sales (P/S): 13.53
• P/FCF Ratio: -7.18
• Enterprise Value/Market Cap: 0.35
• Enterprise Value/Revenue: 2.15
• Enterprise Value/Gross Profit: 3.37
• Enterprise Value/Ebitda: -3.06
• 1Y Price Target: $24.45
• Price Target Upside: 96.70% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13

• Rating: 50 Neutral
• Price Target: $10.00 ▼(-19.55% Downside)

Xencor's overall stock score reflects a company with strong revenue growth but significant challenges in profitability and valuation. The technical analysis indicates bullish momentum, but the stock appears overbought, suggesting caution. The lack of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

Xencor's revenue growth indicates strong market demand and successful partnerships, which are critical for long-term expansion and sustainability.

Technology Platform

Xencor's XmAb technology enhances therapeutic efficacy, providing a competitive edge in developing novel treatments, crucial for future growth.

Balance Sheet Health

A strong balance sheet with low leverage provides financial stability and flexibility to invest in R&D and strategic initiatives.

Negative Factors

Profitability Challenges

Ongoing profitability issues indicate high operational costs or inefficiencies, which may hinder long-term financial performance.

Cash Flow Concerns

Weak cash flow performance may limit Xencor's ability to fund operations and invest in growth, impacting future liquidity and stability.

Return on Equity

Negative ROE suggests that the company is not efficiently using its equity to generate profits, which could affect investor confidence and capital raising.

Xencor Business Overview & Revenue Model

Company Description

Xencor, Inc. is a biopharmaceutical company focused on the development of engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary XmAb technology platform to create novel therapeutics that enhance the efficacy and safety of antibody-based treatments. Xencor's pipeline includes multiple drug candidates that are in various stages of clinical development, targeting significant unmet medical needs in oncology and other therapeutic areas.

How the Company Makes Money

Xencor generates revenue primarily through collaborations and partnerships with larger pharmaceutical companies, which include upfront payments, research funding, and milestone payments tied to the progression of drug candidates through clinical trials. Additionally, the company may earn royalties on future sales of products that are commercialized through these partnerships. Xencor also engages in licensing its XmAb technology platform to other companies, further contributing to its revenue streams. The success of its drug candidates in clinical trials and eventual commercialization are critical factors influencing its earnings.

Xencor Financial Statement Overview

Summary

Xencor's financial performance is mixed. While there is a positive revenue growth rate of 19.38%, the company struggles with profitability, as indicated by negative net profit and EBIT margins. The balance sheet is strong with low leverage, but cash flow issues persist, impacting liquidity.

Income Statement

Xencor's income statement shows a mixed performance. The company has experienced a positive revenue growth rate of 19.38% TTM, indicating potential growth. However, profitability metrics such as the net profit margin and EBIT margin are negative, reflecting ongoing challenges in achieving profitability. The gross profit margin remains high, suggesting efficient cost management at the gross level, but the negative net profit margin highlights significant expenses or losses further down the income statement.

Balance Sheet

The balance sheet reveals a relatively low debt-to-equity ratio of 0.11 TTM, indicating conservative leverage and a strong equity position. However, the return on equity is negative, suggesting that the company is not currently generating positive returns on its equity investments. The equity ratio is stable, reflecting a solid capital structure, but the negative ROE indicates challenges in profitability.

Cash Flow

Xencor's cash flow statement shows a decline in free cash flow growth by -18.63% TTM, which is concerning for future liquidity. The operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from operations relative to its net losses. The free cash flow to net income ratio is slightly above 1, suggesting some ability to cover net losses with free cash flow, but overall cash flow performance remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	164.15M	110.49M	168.34M	164.58M	275.11M	122.69M
Gross Profit	104.70M	110.49M	-85.26M	155.78M	267.62M	-47.11M
EBITDA	-115.24M	-186.17M	-125.87M	-72.16M	51.26M	-71.00M
Net Income	-177.87M	-232.62M	-126.09M	-55.18M	82.63M	-63.54M
Balance Sheet
Total Assets	879.42M	951.95M	952.69M	846.27M	838.21M	703.24M
Cash, Cash Equivalents and Short-Term Investments	443.86M	497.77M	593.73M	623.06M	334.11M	603.00M
Total Debt	212.95M	231.95M	83.43M	59.63M	33.97M	11.63M
Total Liabilities	259.07M	277.92M	283.56M	118.77M	104.71M	130.80M
Stockholders Equity	620.35M	677.61M	668.80M	727.50M	733.50M	572.44M
Cash Flow
Free Cash Flow	-140.81M	-208.28M	63.86M	-18.92M	-32.83M	-18.77M
Operating Cash Flow	-134.18M	-202.19M	85.11M	24.48M	-16.85M	-5.00M
Investing Cash Flow	-52.06M	-7.87M	-111.06M	-119.72M	-46.25M	100.19M
Financing Cash Flow	199.82M	197.15M	26.18M	5.70M	43.04M	18.04M

Xencor Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.43
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XNCR, the sentiment is Positive. The current price of 12.43 is above the 20-day moving average (MA) of 11.50, above the 50-day MA of 9.40, and above the 200-day MA of 11.62, indicating a bullish trend. The MACD of 1.06 indicates Negative momentum. The RSI at 63.54 is Neutral, neither overbought nor oversold. The STOCH value of 79.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XNCR.

Xencor Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	68 Neutral	$1.66B	35.91	18.17%	―	1218.82%	―
RLAY	55 Neutral	$1.12B	―	-46.24%	―	-76.27%	22.77%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XNCR	50 Neutral	$995.67M	―	-29.22%	―	-2.07%	22.52%
AUTL	50 Neutral	$439.13M	―	-52.18%	―	187.52%	26.32%
DNTH	48 Neutral	$1.37B	―	-34.71%	―	17.87%	41.27%
MRVI	41 Neutral	$842.69M	―	-55.41%	―	-22.52%	-37.00%

Xencor Corporate Events

Xencor Appoints Raymond Deshaies to Board of Directors

On July 31, 2025, Xencor announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies, a renowned biochemist and cell biologist with extensive experience in biotechnology and drug development, previously served as senior vice president of global research at Amgen Inc. His appointment is expected to bolster Xencor’s efforts in advancing its pipeline of XmAb drug candidates through clinical development, leveraging his deep understanding of biological mechanisms and track record of translating scientific insights into transformative medicines.

Xencor Holds Annual Stockholders Meeting on June 12

On June 12, 2025, Xencor, Inc. held its Annual Meeting of Stockholders, where 94.68% of the company’s shares were represented. During the meeting, stockholders elected eight directors, ratified KPMG LLP as the independent accounting firm, approved an amendment to increase shares in the Equity Incentive Plan by 3,000,000, and supported the executive compensation plan.